KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-3475, CISPLATIN , GEMCITABINE clinical trials

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

This study looks at a new drug, pembrolizumab (Keytruda), combined with standard chemotherapy for a type of cancer called biliary tract cancer. It aims to see if this combination helps people live longer compared to chemotherapy alone. It's a large study, comparing the two treatments directly.